Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2026 and ...

Irvine-based medical device company Beta Bionics Inc. reports first quarter earnings and raise full-year revenue guidance.

Q1 2026 earnings call recap: 57% sales growth, higher 2026 guidance, pharmacy mix gains, and FDA risk updates—read now.

The framework I introduced was that when our pharmacy installed base in a given quarter exceeds three times the number of new patient starts through pharmacy in that same quarter, the pharmacy channel ...

Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2026 financial results ...

Beta Bionics, Inc., a leader in diabetes management solutions, announced it will release its first quarter financial results for 2025 on May 6, 2025, after market close. Management will hold a ...

Beta Bionics, Inc. BBNX shares rallied 10.3% in the last trading session to close at $13.02. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Beta Bionics’ iLet insulin pump now counts an installed user base of more than 35K Beta Bionics Inc. Chief Executive Sean Saint described the first year of being a public company as a “rollercoaster.” ...

Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results ...